Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary ...

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

Prostate cancer is often resistant to immunotherapy, which harnesses a person's immune system to recognize and destroy tumors. But a new technology that targets RNA in cancer cells gave immunotherapy ...

Prostate cancer is often resistant to immunotherapy, which harnesses a person's immune system to recognize and destroy tumors. But a new technology that targets RNA in cancer cells gave immunotherapy ...